JPH203, a novel and selective SLC7A5 inhibitor, is currently being evaluated in a phase 2 clinical trial in patients with advanced biliary tract cancers (UMIN Clinical Trials Registry UMIN000034080) based on the promising results of the phase 1 clinical trial in patients with advanced solid tumors (37). This evidence concerns the gene SLC7A5 and biliary tract cancer.